Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Drops By 27.0%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 38,600 shares, a decrease of 27.0% from the January 31st total of 52,900 shares. Based on an average trading volume of 74,500 shares, the short-interest ratio is currently 0.5 days. Currently, 1.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. SBI Securities Co. Ltd. acquired a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 66,188 shares of the biotechnology company’s stock, valued at approximately $462,000. SBI Securities Co. Ltd. owned approximately 1.81% of Pulmatrix at the end of the most recent reporting period. 11.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Pulmatrix in a report on Sunday, January 5th. They set a “hold” rating for the company.

Pulmatrix Trading Up 4.7 %

Shares of Pulmatrix stock opened at $8.08 on Monday. The company has a 50 day moving average of $7.12 and a 200-day moving average of $4.62. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $10.40. The company has a market cap of $29.51 million, a PE ratio of -3.06 and a beta of 1.61.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.